Icotrokinra update reports sustained psoriasis clearance through 112 weeks

Johnson & Johnson announced new long-term results on October 2 for icotrokinra, the oral peptide marketed as Icotyde, reporting sustained skin clearance through 112 weeks in the Phase 3 ICONIC-TOTAL psoriasis trial. The update addresses an important question for a chronic disease: whether improvements persist beyond the initial treatment period.

The company reported that 70% of treated patients had clear or almost clear skin overall at Week 112. Complete clearance at individual affected sites was reported in 60% of patients with scalp psoriasis, 89% with genital psoriasis and 63% with hand or foot psoriasis. These are different measures in different patient groups, rather than interchangeable estimates of whole-body clearance.

The findings were presented at the European Academy of Dermatology and Venereology Congress. The newly announced results remain sponsor-reported conference findings; earlier stages of the same trial have been described in peer-reviewed publications.

What the randomized trial established

ICONIC-TOTAL enrolled 311 participants aged 12 or older with plaque psoriasis and at least moderate involvement of the scalp, genital area, hands or feet. Participants were randomly assigned in a two-to-one ratio to icotrokinra or placebo. The study was double-blind during its initial comparison period.

Its primary endpoint was clear or almost clear skin overall at Week 16, together with at least a two-grade improvement on the investigator assessment scale. The published initial results found that approximately 57% of icotrokinra recipients met that endpoint, compared with 6% receiving placebo.

The site-specific results were more nuanced. Clear or almost clear scalp and genital skin occurred significantly more often with icotrokinra. For hands and feet, the corresponding comparison did not reach statistical significance. That distinction matters when interpreting the newer hand-and-foot clearance percentage: a later response rate alone does not establish superiority over a comparator.

Why the longer follow-up needs different interpretation

Placebo recipients transitioned to icotrokinra at Week 16. Consequently, the subsequent follow-up cannot provide the same continuing randomized comparison between active treatment and placebo.

The peer-reviewed one-year report, published in May 2026, described later outcomes as descriptive analyses rather than additional formal hypothesis tests. It counted missing observations as nonresponses through Week 52. Of the original 311 participants, 275 completed treatment through that point.

The October announcement does not provide the Week 112 analysis denominators or explain how missing observations were handled for the reported percentages. Those details are needed to judge how much retention and analysis choices may influence the apparent durability. The one-year methodology should not automatically be assumed to apply to the newer results.

Generalizability also deserves attention. Only six participants in the original trial were adolescents, and most participants were white. Overall results therefore provide limited precision for some patient groups.

Practical meaning and remaining questions

Icotrokinra targets the interleukin-23 receptor, an immune-signaling pathway involved in psoriasis. The update adds information about sustained disease control with an oral peptide, but does not establish that the treatment is preferable to every other systemic option.

Johnson & Johnson reported no newly identified safety signals through Week 112. That statement does not mean adverse effects were absent, and the announcement does not supply a detailed long-term adverse-event table.

The evidence supports continued evaluation of durable skin outcomes. It does not establish reduced cardiovascular risk, longer life or broader effects on biological aging. Full reporting of the two-year population, withdrawals, missing-data methods and adverse events will make the new percentages more clinically interpretable.